2014
DOI: 10.1007/s11095-014-1502-4
|View full text |Cite
|
Sign up to set email alerts
|

Curcumin and Dimethoxycurcumin Induced Epigenetic Changes in Leukemia Cells

Abstract: DMC is a more stable analogue of curcumin that can induce epigenetic changes not induced by curcumin. DMC induced the expression of promoter methylated genes. The combination of DMC with DNA methyltransferase inhibitors could harness their combined induced epigenetic changes for optimal re-expression of epigenetically silenced genes.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
43
0

Year Published

2015
2015
2021
2021

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 42 publications
(43 citation statements)
references
References 41 publications
0
43
0
Order By: Relevance
“…In this present work, we use curcumin as a model drug and aim to provide a novel approach for enhancing the chemical stability of drug molecules loaded in liposome. It is well known that curcumin is a lipophilic molecule and has been extensively used in food, medicines, and cosmetics due to its various bioactivities [17][18][19][20][21]. However, its delivery is highly limited by its insolubility and instability in biological fluids [22][23][24][25].…”
Section: Introductionmentioning
confidence: 99%
“…In this present work, we use curcumin as a model drug and aim to provide a novel approach for enhancing the chemical stability of drug molecules loaded in liposome. It is well known that curcumin is a lipophilic molecule and has been extensively used in food, medicines, and cosmetics due to its various bioactivities [17][18][19][20][21]. However, its delivery is highly limited by its insolubility and instability in biological fluids [22][23][24][25].…”
Section: Introductionmentioning
confidence: 99%
“…In addition, curcumin reduced the expression of the positive regulators of DNMT1, p65 and Sp1, which correlates with reductions in the binding of these transcription factors to the DNMT1 promoter in AML cell lines, demonstrating the promise of curcumin as a potential treatment for AML [29]. More recently, dimethoxycurcumin, a synthetic structural analog of curcumin, along with other epigenetic modifiers [e.g., 5-azacytidine (5AZA) and decitabine], was shown to augment the effect of DNMT inhibitors on DNA methylation to reactivate the silenced genes in leukemia cells [30]. In addition to its regulatory role in blood cancers, curcumin is a potent epigenetic regulatory agent in many solid tumors.…”
Section: Introductionmentioning
confidence: 99%
“…Moreover, recent studies has shown utilization of curcumin in nano formulation and microemulsified forms to increase its bioavailability and site specific action in particular to cancer cells[32, 79,80].Curcumin and its related analogues has also been witnessed to induce epigenetic changes in tumour cells including PC with ability to modulate of histone acetylation by inhibiting histone acetylase [81,82], inducing apoptosis [83], Downregulation of AR and its binding ability [82], regulation of epidermal growth factor receptor(EGFR) tyrosine kinase activity [84,85],inhibition of angiogenesis/vascular endothelial growth factor(VEGF) [86,87], inhibition of cell proliferation in androgen independent and dependent PC cell lines via modulation of Wnt transcriptional activity medicated by low expression of protein in Wnt transcriptional complex [77,[88][89][90][91][92][93].…”
Section: Curcumin (Diferuloylmethane)mentioning
confidence: 99%